All articles tagged with #vir 5500
A masked T-cell engager called VIR-5500 demonstrated early promise in an ongoing advanced prostate cancer trial, with 82% of high-dose patients seeing PSA reductions and about half showing tumor shrinkage; masking aims to reduce inflammatory toxicity and enable safer, slower activation, though results are preliminary and not yet peer-reviewed.
Astellas and Vir Biotechnology announced a global strategic collaboration to co-develop and co-commercialize VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager for prostate cancer; U.S. commercialization led by Astellas (Vir may co-promote), ex-U.S. commercialization to Astellas, development costs shared 60/40 (Astellas/Vir), Vir to receive $335 million upfront/near-term payments and up to $1.37 billion in milestones, with royalties on ex-U.S. net sales and a potential 50/50 U.S. profit/loss share if Vir elects to co-promote; closing subject to customary regulatory clearances.